KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion

Meta-analysis ofKRASmutations and survival after resection of colorectal liver metastases

(2015) K. W. Brudvik et al.   BRITISH JOURNAL OF SURGERY

RAS Mutations Predict Radiologic and Pathologic Response in Patients Treated with Chemotherapy Before Resection of Colorectal Liver Metastases

(2014) Yoshihiro Mise et al.   ANNALS OF SURGICAL ONCOLOGY

Discrepancy Between Recurrence-Free Survival and Overall Survival in Patients with Resectable Colorectal Liver Metastases: A Potential Surrogate Endpoint for Time to Surgical Failure

(2014) Masaru Oba et al.   ANNALS OF SURGICAL ONCOLOGY

Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147

(2014) Wilson I. Gonsalves et al.   JNCI-Journal of the National Cancer Institute

RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases

(2013) Jean-Nicolas Vauthey et al.   ANNALS OF SURGERY

Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases

(2013) Georgios Karagkounis et al.   CANCER

KRASstatus and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab

(2012) S. Stremitzer et al.   BRITISH JOURNAL OF SURGERY

KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer

(2011) J. Tie et al.   CLINICAL CANCER RESEARCH

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

(2011) Timothy S Maughan et al.   LANCET

Predictive and Prognostic Markers in Colorectal Cancer

(2011) Ben George et al.   Current Oncology Reports

Epithelial-to-Mesenchymal Transition and Oncogenic Ras Expression in Resistance to the Protein Kinase C  Inhibitor Enzastaurin in Colon Cancer Cells

(2010) M. Serova et al.   MOLECULAR CANCER THERAPEUTICS

Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer

(2009) Myrddin Rees et al.   ANNALS OF SURGERY

KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

(2009) Susan D. Richman et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

(2008) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY